FindTrial
Sign In

Standard of Care FVIII Replacement therapy

DRUG2 trials

Sponsors

Pfizer, Spark Therapeutics, Inc.

Conditions

Blood Coagulation DisorderBlood Coagulation Disorders, InheritedCoagulation Protein DisordersFactor VIII DeficiencyGenetic Diseases, InbornGenetic Diseases, X-LinkedHematologic DiseasesHemophilia A

Phase 3

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
CompletedNCT03587116
PfizerHemophilia A, Hemophilia B
Start: 2018-07-26End: 2024-12-13Updated: 2025-11-06

Unknown Phase

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
CompletedNCT03876301
Spark Therapeutics, Inc.Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders +6
Start: 2019-01-21End: 2023-05-02Updated: 2023-07-10

Related Papers

Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
Blood2024-11-05
Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis
Blood2023-11-022 citations
Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar Syndrome
Human Gene Therapy2019-09-1060 citations